CellPoint enables clinicians to treat hematological malignancies by retargeting patient immune cells at the point-of-care. Engineered patient T cells using chimeric antigen receptors (CAR-Ts) are a great invention from the last decade, eradicating tumors and providing durable remissions. However, first generation CAR-Ts require shipment of cryopreserved cells to large factories and labor-intensive manual processing, as designe...
CellPoint enables clinicians to treat hematological malignancies by retargeting patient immune cells at the point-of-care. Engineered patient T cells using chimeric antigen receptors (CAR-Ts) are a great invention from the last decade, eradicating tumors and providing durable remissions. However, first generation CAR-Ts require shipment of cryopreserved cells to large factories and labor-intensive manual processing, as designed in the ’90s.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.